The latest price trend of Erdafitinib in 2026 and the key factors affecting drug prices

Erdafitinib (Erdafitinib), as a FGFR inhibitor, is mainly used to treat advanced or metastatic urothelial carcinoma carrying FGFR mutations. Since its launch in China, as it has not yet been included in medical insurance, domestic drug prices are generally high and fluctuate greatly. Patients may face higher costs and channel restrictions when purchasing directly. This makes drug availability and frequency of use partly influenced by economic factors.

In overseas markets, the original drug of erdafitinib is mainly the Hong Kong version, which sells for more than 20,000 yuan per box and can only be obtained through Hong Kong pharmacies. The prices of such original drugs remain high due to factors such as high research and development costs, limited supply chains, and cross-border transportation costs. For domestic patients, purchasing original drugs directly from overseas is not only expensive, but may also involve transportation and legality issues, so they need to choose carefully.

In comparison, the prices of foreign generic drugs are more affordable, mainly from Laos and Bangladesh Yaopin International, with prices ranging from a few hundred yuan to more than 2,000 yuan. The ingredients of generic drugs are basically the same as those of original drugs. Therefore, while ensuring the efficacy, they can significantly reduce the financial burden on patients. The price of generic drugs is affected by production costs, exchange rate fluctuations, supply channels and international trade policies, and there is a certain degree of volatility, but overall it is more acceptable to patients than original drugs.

The price trend of erdafitinib in the future may be affected by many factors, including medical insurance inclusion, the progress of domestic and foreign generic drug launches, patient demand, and exchange rate changes. If domestic medical insurance can cover the drug, it is expected that the price will trend downward. At the same time, the launch and competition of generic drugs will further stabilize or reduce prices, allowing more patients to afford and continue to use the drug.

Keyword tags:

Erdafitinib, price trend,2026Year forecast, influencing factors, medical insurance, generic drugs, market supply, exchange rate fluctuations

Reference materials:https://www.cancer.gov/about-cancer/treatment/drugs/erdafitinib